Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-17T17:36:55.262Z Has data issue: false hasContentIssue false

Imipramine in Chronic Depression

Published online by Cambridge University Press:  08 February 2018

P. A. Barker
Affiliation:
The Royal Edinburgh Hospital for Mental and Nervous Disorders (Craig House Section)
G. W. Ashcroft
Affiliation:
The Royal Edinburgh Hospital for Mental and Nervous Disorders (Craig House Section)
J. K. Binns
Affiliation:
The Royal Edinburgh Hospital for Mental and Nervous Disorders (Craig House Section)
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Imipramine hydrochloride (N-(γ-dimethylaminopropyl)-iminodibenzyl hydrochloride, “Tofranil”) has been shown by many investigators to be of value in the treatment of depressive states. The reports of Kuhn (1957, 1958) and of Kielholz and Battegay (1958) have been followed by confirmatory papers from other authors. A number of contributors to the McGill University Symposium on Depression and Allied States (1959) commented favourably on the value of imipramine in depression; Hoff, however, while agreeing that the drug is useful in acute depressions stated that he found it ineffective in chronic depression.

Information

Type
Original Articles
Copyright
Copyright © Royal College of Psychiatrists, 1960 
Submit a response

eLetters

No eLetters have been published for this article.